Novo Nordisk will cut production of Victoza to boost supply of Ozempic

Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy reducing production of diabetes drug Victoza to make more Ozempic.

Novo and the European Medicines Agency (EMA) divulged (PDF) the move in a letter to healthcare professionals, warning of a growing shortage of both medicines that is set to intensify during the rest of the fourth quarter.

With the shortage of Victoza expected to continue into the second quarter of next year, the EMA has instructed healthcare providers not to start new patients on the drug until then. While Victoza (liraglutide) and Ozempic (semaglutide) are both GLP-1 drugs, the former—which was originally approved in 2010—is not used for weight loss.

Intermittent shortages of Ozempic are expected to persist throughout 2024, though the overall supply situation should improve in the first quarter of next year, according to the letter. Novo Nordisk will limit the supply of starter doses of Ozempic (0.25 mg) to help curb the initiation of new patients, the company said. During this period, the EMA has also recommended that doctors “limit” new users.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!